Entero Healthcare Solutions Ltd

Entero Healthcare Solutions Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend. This change comes amid a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture for investors in this small-cap retailing stock.

Entero Healthcare Solutions Ltd is rated Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Entero Healthcare Solutions Ltd demonstrated a robust intraday performance on 18 Mar 2026, surging 7.12% to touch a day’s high of Rs 1098.45. The stock outperformed its sector and the broader market, continuing its recent upward momentum with notable trading activity.

Entero Healthcare Solutions Ltd is rated Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into its performance and outlook.

Entero Healthcare Solutions Ltd has seen its investment rating downgraded from Hold to Sell by MarketsMOJO as of 25 February 2026, reflecting a reassessment across key parameters including valuation, financial trends, quality, and technical indicators. Despite some positive financial results, the stock’s underperformance relative to the broader market and evolving valuation metrics have prompted a more cautious stance.

Entero Healthcare Solutions Ltd has seen its investment rating upgraded from Sell to Hold as of 20 February 2026, reflecting significant improvements in valuation metrics, financial performance, and technical indicators. Despite recent underperformance relative to the broader market, the company’s fundamentals and attractive valuation have prompted a reassessment of its outlook within the retailing sector.

Entero Healthcare Solutions Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive price range, according to the latest analysis. This change, driven by key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positions the stock as a compelling consideration within the retailing sector despite recent market headwinds.

Entero Healthcare Solutions Ltd experienced a significant intraday decline on 16 Feb 2026, touching a low of Rs 1,060, reflecting an 8.19% drop as the stock faced notable selling pressure amid a volatile trading session.

Entero Healthcare Solutions Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by a reassessment of its valuation metrics and recent market underperformance despite solid financial results. The company’s quality, financial trend, and technical parameters have also been analysed, revealing a mixed picture that ultimately led to a cautious stance by analysts.

Entero Healthcare Solutions Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Sell. This article analyses the evolving price attractiveness of the stock through key valuation metrics, peer comparisons, and recent market performance, providing investors with a comprehensive view of its current standing in the retailing sector.

Entero Healthcare Solutions Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Entero Healthcare Solutions Ltd., a small-cap pharmaceutical retailer with a market capitalisation of ₹5,000.93 crores, reported a mixed performance in Q3 FY26 (October-December 2025), with robust revenue expansion overshadowed by a sequential decline in profitability. The company posted a consolidated net profit of ₹27.63 crores for the quarter, declining 12.56% quarter-on-quarter (QoQ) from ₹31.60 crores in Q2 FY26, though still managing an 8.61% year-on-year (YoY) improvement from ₹25.44 crores in Q3 FY25. Net sales surged to ₹1,706.52 crores, marking an 8.63% QoQ increase and a healthy 25.57% YoY growth, demonstrating the company's continued ability to scale its retail operations despite profitability headwinds.

Entero Healthcare Solutions Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 February 2026, providing investors with the most recent insights into the company’s performance and outlook.